A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors.

Thomas Benjamin KarasicE Gabriela ChioreanSaid M SebtiPeter J O'Dwyer

Published in: Targeted oncology (2020)

GGTI2418 was safe and tolerable at all tested dose levels with some evidence of disease stability. Due to rapid elimination, dosing of GGTI2418 in this study may have been inadequate to achieve optimal inhibition of its target, GGTase I.

Keyphrases